Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biotech Backers Are Learning to Live with Exit-by-Earn-out

Mar 01 2010

• By Chris Morrison and Ellen Licking

Related Content

OrbiMed Closes $550 Million Fund

Mar 01 2010

Biopharma VC Exits 2005-2007: Cheap IPOs, Expensive Acquisitions

Jan 01 2008

2009's Private Biotech Acquisitions Are a Tale of Two Step-Ups

Jan 01 2010

Private Biotech M&A Review: Has the Market Lost Steam?

Sep 01 2008

For a Look at IPO Future, Follow the Follow-On?

Sep 01 2009

For Funds Close to Empty, Filling Stations May Be Hard to Find

Sep 01 2009

Reacting to the Crisis: Biotech Venture Capital's Plan B

Dec 01 2008

Ironwood IPO Raises Plenty Of Cash And Plenty Of Questions For Biotech Investors

Feb 03 2010

Anthera Takes A "Haircut" And Delays Its Planned Initial Stock Offering

Feb 24 2010

Venture Data Continues To Haunt The Biotech Landscape

Jan 15 2010

The Price is Wrong: Finding Alternatives to Traditional IPOs

Jun 01 2006

Bad Haircuts: 2005's Biotech IPOs--Getting Out at Any Price?

Mar 01 2005

Related Companies

Anthera Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Mead Johnson Nutrition Co.

Omeros Corporation

Trius Therapeutics, Inc.

AVEO Pharmaceuticals, Inc.

inRegen

Ironwood Pharmaceuticals, Inc.

Sirtris Pharmaceuticals

Omrix Biopharmaceuticals

GSK plc

Valneva SE

Johnson & Johnson

Vertex Pharmaceuticals Incorporated

Shionogi & Co. Ltd.

BioMarin Pharmaceutical Inc.

Novartis AG

Orexo AB

Silence Therapeutics plc

Eisai Co., Ltd.

Cephalon, Inc.

Ception Therapeutics

Human Genome Sciences, Inc.

Additional Topics

Business Strategies BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window